Trial Profile
A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intramuscularly on a two-dose schedule to subjects who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) studies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Registrational
- Acronyms Zoster-056
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 01 Dec 2020 Results published in the Vaccine
- 16 May 2019 Status changed from active, no longer recruiting to completed.
- 04 May 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.